| 000 | 01821 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514194837.0 | ||
| 264 | 0 | _c20050216 | |
| 008 | 200502s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1704642 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDevetten, M P | |
| 245 | 0 | 0 |
_aThiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cOct 2004 |
||
| 300 |
_a577-80 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xmortality |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 |
_aLeukemia, Myeloid _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRadiation Dosage |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aThiotepa _xadministration & dosage |
| 650 | 0 | 4 | _aTransplantation Conditioning |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aWhole-Body Irradiation |
| 700 | 1 | _aQazilbash, M H | |
| 700 | 1 | _aBeall, C L | |
| 700 | 1 | _aBunner, P | |
| 700 | 1 | _aWeisenborn, R | |
| 700 | 1 | _aLynch, J P | |
| 700 | 1 | _aEricson, S G | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 34 _gno. 7 _gp. 577-80 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1704642 _zAvailable from publisher's website |
| 999 |
_c14987773 _d14987773 |
||